NFKB1 and B-cell chronic lymphocytic leukemia: Treatment of CLL cells with the NF-κB inhibitor IT-901 reduced NF-κB phosphorylation and strongly decreased the mRNA levels of CCR2, CXCR3 and CCR7 (Figures 5A–C) without significantly affecting cell viability (Supplementary Figure 4), supporting the notion that NF-κB activation plays a key role in the coordinated transcriptional control of CCR2, CXCR3 and CCR7 in CLL cells.